𝔖 Bobbio Scriptorium
✦   LIBER   ✦

BRCA1promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients

✍ Scribed by Jasmina Z. Cerne, Lin Zong, Jaroslav Jelinek, Susan G. Hilsenbeck, Tao Wang, Steffi Oesterreich, Sean E. McGuire

Book ID
118796644
Publisher
Springer US
Year
2012
Tongue
English
Weight
318 KB
Volume
135
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Angiogenesis does not predict clinical r
Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer
✍ Trond Paulsen; Turid Aas; Anne-Lise Borresen; Jan Erik Varhaug; Per E. LΓΈnning; πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 43 KB πŸ‘ 2 views

## Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer The prognostic importance of angiogenesis in breast cancer has recently been discussed, and a significant relationship between vascular density and survival has been descri

p53 status influences response to tamoxi
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines
✍ Lynnette Fernandez-Cuesta; Suresh Anaganti; Pierre Hainaut; Magali Olivier πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 439 KB

## Abstract Mutations in the tumor suppressor gene __TP53__ are associated with poor prognosis in breast cancer. This prognostic value may rely in part on the fact that p53 plays a role in the antiproliferative and apoptotic activities of chemotherapy regimens used to treat breast tumors. However,